Monimus Capital Management LP Purchases Shares of 364,306 CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Monimus Capital Management LP purchased a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 364,306 shares of the biotechnology company’s stock, valued at approximately $375,000.

Several other hedge funds also recently added to or reduced their stakes in CTMX. Miller Financial Services LLC acquired a new position in shares of CytomX Therapeutics in the fourth quarter worth about $26,000. Traphagen Investment Advisors LLC acquired a new position in shares of CytomX Therapeutics in the fourth quarter worth about $31,000. US Bancorp DE acquired a new position in shares of CytomX Therapeutics in the third quarter worth about $40,000. Virtu Financial LLC acquired a new position in shares of CytomX Therapeutics in the third quarter worth about $104,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of CytomX Therapeutics by 10.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock worth $331,000 after acquiring an additional 26,373 shares during the period. 67.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Wedbush restated an “outperform” rating and set a $5.00 price target on shares of CytomX Therapeutics in a research report on Friday, March 7th. StockNews.com upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, March 10th. Finally, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research report on Friday, March 7th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $5.02.

CytomX Therapeutics Trading Up 10.0 %

CytomX Therapeutics stock opened at $0.65 on Friday. The stock has a market cap of $52.03 million, a P/E ratio of 3.82 and a beta of 1.05. The company has a fifty day simple moving average of $0.80 and a 200-day simple moving average of $1.00. CytomX Therapeutics, Inc. has a 12-month low of $0.56 and a 12-month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.45. The company had revenue of $38.09 million for the quarter, compared to analyst estimates of $13.53 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. As a group, sell-side analysts forecast that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.